Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus - Scorecard - MDSpire

Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus

  • By

  • Sarah M. Ostrowski

  • Paul R. Hartmeier

  • Madeline A. Lipp

  • Timothy Perkins

  • Elliot Reed

  • Xiyue Li

  • Wilson S. Meng

  • Kerry M. Empey

  • June 26, 2026

  • 0 min

Share

Clinical Scorecard: Intranasal Administration of a Nanoparticle-Based Subunit Vaccine to Elicit Protective Immunity Against Respiratory Syncytial Virus

At a Glance

CategoryDetail
ConditionRespiratory Syncytial Virus (RSV)
Key MechanismsIntranasal delivery of a biotinylated nanoparticle-based subunit vaccine enhances immune response and establishes antiviral memory T cells.
Target PopulationChildren under the age of 5
Care SettingVaccine development and immunization research

Key Highlights

  • RSV is the leading cause of lower respiratory tract infections in young children.
  • Current maternal vaccines and monoclonal antibodies provide limited duration of protection.
  • The intranasal PreF-bNP vaccine demonstrated complete RSV protection in preimmune mouse models.
  • The vaccine formulation allows for dose optimization of antigens and adjuvants.
  • Intranasal vaccination generates stronger mucosal immune responses compared to intramuscular delivery.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • Live attenuated vaccines may pose a risk of life-threatening infections.

        Patient & Prescribing Data

        Young children at risk for severe RSV disease.

        The PreF-bNP vaccine formulation is designed to provide safe, long-term protection against RSV.

        Clinical Best Practices

        • Utilize subunit vaccines to avoid safety risks associated with live attenuated vaccines.
        • Co-formulate subunit vaccines with immune-stimulating adjuvants for enhanced immune response.
        • Optimize antigen and adjuvant dosing through a flexible vaccine design.

        Related Resources & Content

        Original Source(s)

        Intranasal delivery of a polymeric nanoparticle subunit vaccine for the induction of protective immunity against respiratory syncytial virus

        • by Sarah M. Ostrowski, Paul R. Hartmeier, Madeline A. Lipp, Timothy Perkins, Elliot Reed, Xiyue Li, Wilson S. Meng, Kerry M. Empey

        • June 26, 2026

        Related Content

        Acute acalculous cholecystitis in children due to EBV and cytomegalovirus infection: a rare case report and review of the literature

        Weekly HIV Regimen Meets Phase 3 Goal

        The investigational combination pairs islatravir and lenacapavir in a once-weekly single-tablet regimen.

        Rare or Unverified Outcomes Shape Vaccine Safety and Gender Care Debates — The Monitor